BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,067 filers reported holding BAXTER INTL INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $9,226,000 | +12.9% | 124,945 | -0.6% | 0.04% | +8.3% |
| Q1 2018 | $8,172,000 | +156.9% | 125,657 | +155.4% | 0.04% | +157.1% |
| Q4 2017 | $3,181,000 | +48.3% | 49,201 | +43.9% | 0.01% | +16.7% |
| Q3 2017 | $2,145,000 | -36.5% | 34,184 | -38.8% | 0.01% | -36.8% |
| Q2 2017 | $3,379,000 | +65.7% | 55,818 | +42.0% | 0.02% | +11.8% |
| Q1 2017 | $2,039,000 | -70.2% | 39,304 | -74.5% | 0.02% | -65.3% |
| Q4 2016 | $6,840,000 | +63.8% | 154,235 | +75.8% | 0.05% | +58.1% |
| Q3 2016 | $4,176,000 | +87.3% | 87,725 | +77.9% | 0.03% | +82.4% |
| Q2 2016 | $2,229,000 | -21.6% | 49,300 | -28.8% | 0.02% | -26.1% |
| Q1 2016 | $2,843,000 | -73.2% | 69,200 | -75.2% | 0.02% | -36.1% |
| Q4 2015 | $10,628,000 | +112.0% | 278,590 | +82.6% | 0.04% | +33.3% |
| Q3 2015 | $5,013,000 | +75.9% | 152,600 | +266.8% | 0.03% | +28.6% |
| Q1 2015 | $2,850,000 | -55.4% | 41,600 | -52.3% | 0.02% | -56.2% |
| Q4 2014 | $6,390,000 | +692.8% | 87,200 | +676.9% | 0.05% | +700.0% |
| Q3 2014 | $806,000 | -84.4% | 11,224 | -84.0% | 0.01% | -86.4% |
| Q1 2014 | $5,157,000 | -42.5% | 70,100 | -45.7% | 0.04% | -30.2% |
| Q4 2013 | $8,972,000 | +48.2% | 129,000 | +39.9% | 0.06% | +425.0% |
| Q3 2013 | $6,056,000 | -5.5% | 92,198 | -0.3% | 0.01% | -50.0% |
| Q2 2013 | $6,408,000 | – | 92,505 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |